Antibacterial Therapeutics And Prophylactics

Vyome Biosciences Pvt. Ltd.
Granted App No 201847004096 Patent 466679 Chemical

Patent information

IP India · live record
Application number
201847004096
Filing date
02 February 2018
Status
Granted
Legal status
Under Extension Period
Publication number
06/2018
Publication type
INA
Invention field
Chemical
Patent number
466679
Grant date
07 November 2023
Next renewal due
28 July 2025Overdue

Abstract

The present disclosure relates generally to novel molecules compositions and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Applicants

1
India
VYOME BIOSCIENCES PVT. LTD. PLOT NO. 465 Ground Floor, Patparganj Industrial Area, New Delhi, 110092

Inventors

9
India
SENGUPTA, Shiladitya66, Kamayani Kunj, 69 I.P Extension, New Delhi - 110092
India
GHOSH, ShamikA-304, Saraswati Apartment, Plot No. 97, I.P. Extension, New Delhi - 110092
India
GHOSH, SumanaPrince Apartment, Plot No. 54, Flat No. C-402, I.P. Extension, New Delhi - 110092
India
SINHA, MauFlat No. A-1704, Amrapali Eden Park, Plot No. F-27, Sector - 50, Noida, Uttar Pradesh -201301
India
SADHASIVAM, SureshAnna Nagar Second Street, Ponnammapet, Salem, Tamil Nadu - 636001
India
BHATTACHARYYA, AnamikaC-202, Mayurdhwaj Apartments, Plot# 60, I.P. Extension, Patparganj, New Delhi - 110092
India
MAVUDURU, Siva GaneshDoor No: 20-126, Bharatnagar Road, Prahalladapuram, Visakhapatnam, Andhra Pradesh - 530027
India
TANDON, NupurX/79, Pratap Street Gandhi Nagar, New Delhi - 110031
India
KUMAR, Deepak#101/5 Gali No. 9, Nand Colony 2, Pehowa, District Kurukshetra Haryana 136128

Claims

18
1 A compound selected from the group consisting of: (i) a compound of Formula (I): FORMULA I wherein: X is C, N, or CRg; Ri is a C1-C3 alkyl or cyclopropyl, or R! forms a link to X or R2; R2 is H, SH or alkyl; R3 is H or halo; R8 is H, Ci-Cealkyl, Ci-Cealkoxy or halo; A is absent or a linker; B is absent or a linker; and R4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents, or II ' 'p R4is Y K , where p is 0-10; M is CH, NH, orS;YisNH, CH, O or S; L is a linker or Z; and Z is NH2, OH, SH, alkyl, -COOH, or CONH2, (ii) a compound of Formula (II): wherein: XisO, S, orN; Ri is H, Ci-C6alkyl, -COCHY2, -COCH2Y, haloalkyl, CH2CN, amino, OCH3, COOCH3, SO2CH3, COCHjOH, or -[NHC(R7)]n-M; R2 and R3 are independently H or halo; R4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is Y P Where p is 0-10; M is CH, NH, or S; Y is NH, CH, O or S; L is a linker or Z; and Z is NH2, OH, SH, alkyl, -COOH, or CONH2; or R4 is a a carbohydrate, (iii) a compound of Formula (III): FORMULA III wherein: (a) n is 1; X and Y are oxygen atom; W is carbon atom; Z is absent; R! is hydrogen atom, hydroxyl, methoxy, amino, -NH-(CH2)P-R, where p is 0, 1, 2, 3, 4 or 5; R is hydrogen atom, amine, guanidine, piperazine, morpholine, NHCOCH3, NHS02CH3, NHS02-C6H5 or -L!-B-R7; L! is -(CH2)q-, -(CH2)q-CH=CH-(CH2)q-, _(CH2)q-0-(CH2)q-, -(CH2)q- NH-(CH2)q-, where q is 0, 1, 2 or 3; A and B are independently a cyclyl, heterocyclyl, aryl or heteroaryl, where the cyclyl, heterocyclyl, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R7 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is -L1-A-R7; R3 is H; R4 and R5 independently are hydrogen, halogen, hydroxyl, or -0-(CH2)t-R8, where Rg is Q-Cealkyl, amino, di(Ci-C6alkyl)amino, aminocyclopropane, aminocyclopentane, piperazino, or morpholine, and t is 0-10; or (b) n is 1; X and W are carbon atom, or X is carbon atom and W is nitrogen atom; Y is -NH(CH2)q-R6 or (CH2)q-R6, where q = 0 to 10; R6 is -COOH, amine, guanidine, piperazine, morpholine; Z is hydrogen, methyl, NHR, COCH3, S02CH3, or -NH-(CH2)i-COOH, where 1 is 0-10; Ri and R3 independently hydrogen atom, hydroxyl, methoxy, amino, or -Li- A-R6 R is CH3, -(CH2)p-CH3, where p= 0 to 10; U is -(CH2)n-, -(CH2)t-CH=CH-(CH2)t-, _(CH2)t-0-(CH2)t-, -(CH2)t-NH- (CH2)t-, where t is 0, 1, 2, or 3; A is cyclyl, heterocycly, aryl or heteroaryl, where the cyclyl, heterocycly, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R6 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is hydrogen atom; R4 and R5 are independently hydrogen, halogen, hydroxyl, or -0(CH2)X-R8, where R8 is CrC6alkyl, amino, di( N(CH3)2, N(C2H5)2, N(7-Pr)2j aminocyclopropane, aminocyclopentane, piperazino or morpholine, and x is 0-10, or (c) n is 2; X and W are carbon atom; Y is -NH(CH2)q-R6 or (CH2)q-R6, where q = 0 to 10; R6 is -COOH, amine, guanidine, piperazine, morpholine; Z is hydrogen, methyl, NHR, COCH3, S02CH3, or -NH-(CH2)i-COOH, where 1 is 0-10; Ri and R3 independently hydrogen atom, hydroxyl, methoxy, amino, or -Li-A-R6 R is CH3, -(CH2)P-CH3, where p= 0 to 10; U is -(CH2)n-, -(CH2)t-CH=CH-(CH2)t-, _(CH2)t-0-(CH2)t-, -(CH2)t-NH-(CH2),-, where t is 0, 1, 2, or 3; A is cyclyl, heterocycly, aryl or heteroaryl, where the cyclyl, heterocycly, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R6 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3 NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is hydrogen atom; R4 and R5 are independently hydrogen, halogen, hydroxyl, or -0(CH2)x-R8 where R8 is Ci-C6alkyl, amino, di( N(CH3)2, N(C2H5)2, N(7-Pr)2, aminocyclopropane, aminocyclopentane, piperazino or morpholine, and x is 0-10, and (iv) a compound of Formula (IV): FORMULA IV wherein: B is absent or a linker; and Ri is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R! is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R! is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents, /) a compound of Formula (V): FORMULA V wherein: X and Z are independently C or N; Y is C, N or O; Ri is H or -LrA; R2 and R3 are independently O or S; R4 is hydrogen, oxygen, sulphur, hydroxyl, methoxy or -L2-B; R5, R6, R7 and R8 are independently, hydrogen, hydroxyl, fluoro, chloro, bromo, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, amino substituted hexose, or guanidine; L! is absent, a bond or a linker; L2 is absent, a bond or a linker; A and B are independently a cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents, (vi) a compound of Formula (VI): FORMULA VI wherein: X and Z are independently C or N; Y is CH2, NH or O; Ri can be H, OH or -Li-A; R3 is hydrogen, OH, oxygen, sulphur, hydroxyl, methoxy or -L2-B; R4 is O or S; R5, R6, R7 and Rg are independently hydrogen, hydroxyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, amino substituted hexose, or guanidine; L! is absent, a bond or a linker; L2 is absent, a bond or a linker; and A and B are independently cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents, and (vii) a compound of Formula (VII): wherein: X is CHR12, C=R13, NH, S or O; YisOorS; Ri can be H, alkylamino, -OH, -NH(CH2)2NH2or -LrA; R2 and R3 are independently hydrogen, hydroxyl of or -L2-B; R4 and R5 are independently H, halo, hydroxyl, or -(CH2)n-0-(CH2)n-D-R8, - (CH2)n-NH-(CH2)n-D-R8; R8 is H, hydroxyl, halo, trifluoromehtyl, alkyl, alkoxy, acyloxy, amino, dialkylamino, -C02H, nitro, nitrile or-NHS02CH3; Ri2 is H, amino, hydroxyl, or thiol; R13 is O, S or NH; Li is absent, a bond or a linker; L2 is absent, a bond or a linker; A, B and D are independently cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents; and n is 0, 1, 2 or 3. The compound of claim 1, wherein the compound is selected from the group consisting of:
3 A pharmaceutical composition comprising a compound of claim 1 or 2 and a pharmaceutical^ acceptable carrier or excipient.
4 A composition for topical application comprising a compound of claim 1 or 2.
5 A composition for oral administration comprising a compound of claim 1 or 2.
6 A composition for administration by injection comprising a compound of claim 1 or 2.
7 A composition comprising a polymer matrix and a compound of claim 1 or 2.
8 A method for treating an infection, the method comprising administering a therapeutically effective amount of a compound of claim 1 or 2 to a subject in need thereof.
9 The method of claim 8, wherein said infection is caused by a resitant pathogen.
10 The method of claim 8, wherein said infection is caused by a methicillin resistant or vancomycin-resistant pathogen.
11 The method of claim 8, wherein said infection is caused by a quinolone resistant pathogen.
12 A method for wound treatment, the method comprising applying a compound of claim 1 or 2 to a wound.
13 A method for preventing or reducing infection caused by an implant, the method comprising applying a compound of claim 1 or 2 to the implant.
14 A method for preventing or reducing infection caused by an implant, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.
15 A method for the treatment of pneumonia, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.
16 A method for the treatment of urinary tract infection, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.
17 A method for the treatment of impetigo, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.
18 A method for the treatment of acne, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.
19 A method of inhibiting or reducing biofilm formation, the method comprising applying a compound of claim 1 or 2 to a surface or biofilm.

Specification

Show full textCollapse

We claim: 1. A compound selected from the group consisting of: (i) a compound of Formula (I): FORMULA I wherein: X is C, N, or CRg; Ri is a C1-C3 alkyl or cyclopropyl, or R! forms a link to X or R2; R2 is H, SH or alkyl; R3 is H or halo; R8 is H, Ci-Cealkyl, Ci-Cealkoxy or halo; A is absent or a linker; B is absent or a linker; and R4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents, or II ' 'p R4is Y K , where p is 0-10; M is CH, NH, orS;YisNH, CH, O or S; L is a linker or Z; and Z is NH2, OH, SH, alkyl, -COOH, or CONH2, (ii) a compound of Formula (II):

wherein: XisO, S, orN; Ri is H, Ci-C6alkyl, -COCHY2, -COCH2Y, haloalkyl, CH2CN, amino, OCH3, COOCH3, SO2CH3, COCHjOH, or -[NHC(R7)]n-M; R2 and R3 are independently H or halo; R4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is Y P Where p is 0-10; M is CH, NH, or S; Y is NH, CH, O or S; L is a linker or Z; and Z is NH2, OH, SH, alkyl, -COOH, or CONH2; or R4 is a a carbohydrate, (iii) a compound of Formula (III): FORMULA III wherein: (a) n is 1; X and Y are oxygen atom; W is carbon atom; Z is absent; R! is hydrogen atom, hydroxyl, methoxy, amino, -NH-(CH2)P-R, where p is 0, 1, 2, 3, 4 or 5; R is hydrogen atom, amine, guanidine, piperazine, morpholine, NHCOCH3, NHS02CH3, NHS02-C6H5 or -L!-B-R7; L! is -(CH2)q-, -(CH2)q-CH=CH-(CH2)q-, _(CH2)q-0-(CH2)q-, -(CH2)q- NH-(CH2)q-, where q is 0, 1, 2 or 3; A and B are independently a cyclyl, heterocyclyl, aryl or heteroaryl, where the cyclyl, heterocyclyl, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents;

R7 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is -L1-A-R7; R3 is H; R4 and R5 independently are hydrogen, halogen, hydroxyl, or -0-(CH2)t-R8, where Rg is Q-Cealkyl, amino, di(Ci-C6alkyl)amino, aminocyclopropane, aminocyclopentane, piperazino, or morpholine, and t is 0-10; or (b) n is 1; X and W are carbon atom, or X is carbon atom and W is nitrogen atom; Y is -NH(CH2)q-R6 or (CH2)q-R6, where q = 0 to 10; R6 is -COOH, amine, guanidine, piperazine, morpholine; Z is hydrogen, methyl, NHR, COCH3, S02CH3, or -NH-(CH2)i-COOH, where 1 is 0-10; Ri and R3 independently hydrogen atom, hydroxyl, methoxy, amino, or -Li- A-R6 R is CH3, -(CH2)p-CH3, where p= 0 to 10; U is -(CH2)n-, -(CH2)t-CH=CH-(CH2)t-, _(CH2)t-0-(CH2)t-, -(CH2)t-NH- (CH2)t-, where t is 0, 1, 2, or 3; A is cyclyl, heterocycly, aryl or heteroaryl, where the cyclyl, heterocycly, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R6 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is hydrogen atom; R4 and R5 are independently hydrogen, halogen, hydroxyl, or -0(CH2)X-R8, where R8 is CrC6alkyl, amino, di( N(CH3)2, N(C2H5)2, N(7-Pr)2j aminocyclopropane, aminocyclopentane, piperazino or morpholine, and x is 0-10, or (c) n is 2; X and W are carbon atom; Y is -NH(CH2)q-R6 or (CH2)q-R6, where q = 0 to 10; R6 is -COOH, amine, guanidine, piperazine, morpholine;

Z is hydrogen, methyl, NHR, COCH3, S02CH3, or -NH-(CH2)i-COOH, where 1 is 0-10; Ri and R3 independently hydrogen atom, hydroxyl, methoxy, amino, or -Li-A-R6 R is CH3, -(CH2)P-CH3, where p= 0 to 10; U is -(CH2)n-, -(CH2)t-CH=CH-(CH2)t-, _(CH2)t-0-(CH2)t-, -(CH2)t-NH-(CH2),-, where t is 0, 1, 2, or 3; A is cyclyl, heterocycly, aryl or heteroaryl, where the cyclyl, heterocycly, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R6 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3 NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is hydrogen atom; R4 and R5 are independently hydrogen, halogen, hydroxyl, or -0(CH2)x-R8 where R8 is Ci-C6alkyl, amino, di( N(CH3)2, N(C2H5)2, N(7-Pr)2, aminocyclopropane, aminocyclopentane, piperazino or morpholine, and x is 0-10, and (iv) a compound of Formula (IV): FORMULA IV wherein: B is absent or a linker; and Ri is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R! is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R! is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents, /) a compound of Formula (V):

FORMULA V wherein: X and Z are independently C or N; Y is C, N or O; Ri is H or -LrA; R2 and R3 are independently O or S; R4 is hydrogen, oxygen, sulphur, hydroxyl, methoxy or -L2-B; R5, R6, R7 and R8 are independently, hydrogen, hydroxyl, fluoro, chloro, bromo, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, amino substituted hexose, or guanidine; L! is absent, a bond or a linker; L2 is absent, a bond or a linker; A and B are independently a cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents, (vi) a compound of Formula (VI): FORMULA VI wherein: X and Z are independently C or N; Y is CH2, NH or O; Ri can be H, OH or -Li-A; R3 is hydrogen, OH, oxygen, sulphur, hydroxyl, methoxy or -L2-B; R4 is O or S; R5, R6, R7 and Rg are independently hydrogen, hydroxyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, amino substituted hexose, or guanidine;

L! is absent, a bond or a linker; L2 is absent, a bond or a linker; and A and B are independently cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents, and (vii) a compound of Formula (VII): wherein: X is CHR12, C=R13, NH, S or O; YisOorS; Ri can be H, alkylamino, -OH, -NH(CH2)2NH2or -LrA; R2 and R3 are independently hydrogen, hydroxyl of or -L2-B; R4 and R5 are independently H, halo, hydroxyl, or -(CH2)n-0-(CH2)n-D-R8, - (CH2)n-NH-(CH2)n-D-R8; R8 is H, hydroxyl, halo, trifluoromehtyl, alkyl, alkoxy, acyloxy, amino, dialkylamino, -C02H, nitro, nitrile or-NHS02CH3; Ri2 is H, amino, hydroxyl, or thiol; R13 is O, S or NH; Li is absent, a bond or a linker; L2 is absent, a bond or a linker; A, B and D are independently cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents; and n is 0, 1, 2 or 3. The compound of claim 1, wherein the compound is selected from the group consisting of:

3. A pharmaceutical composition comprising a compound of claim 1 or 2 and a pharmaceutical^ acceptable carrier or excipient. 4. A composition for topical application comprising a compound of claim 1 or 2. 5. A composition for oral administration comprising a compound of claim 1 or 2. 6. A composition for administration by injection comprising a compound of claim 1 or 2. 7. A composition comprising a polymer matrix and a compound of claim 1 or 2. 8. A method for treating an infection, the method comprising administering a therapeutically effective amount of a compound of claim 1 or 2 to a subject in need thereof. 9. The method of claim 8, wherein said infection is caused by a resitant pathogen. 10. The method of claim 8, wherein said infection is caused by a methicillin resistant or vancomycin-resistant pathogen. 11. The method of claim 8, wherein said infection is caused by a quinolone resistant pathogen. 12. A method for wound treatment, the method comprising applying a compound of claim 1 or 2 to a wound. 13. A method for preventing or reducing infection caused by an implant, the method comprising applying a compound of claim 1 or 2 to the implant. 14. A method for preventing or reducing infection caused by an implant, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 15. A method for the treatment of pneumonia, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 16. A method for the treatment of urinary tract infection, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.

17. A method for the treatment of impetigo, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 18. A method for the treatment of acne, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 19. A method of inhibiting or reducing biofilm formation, the method comprising applying a compound of claim 1 or 2 to a surface or biofilm.

Documents

Sign in to open
Application documents
1 201847004096-STATEMENT OF UNDERTAKING (FORM 3) [02-02-2018(online)].pdf 02 Feb 2018
2 201847004096-POWER OF AUTHORITY [02-02-2018(online)].pdf 02 Feb 2018
3 201847004096-FORM 1 [02-02-2018(online)].pdf 02 Feb 2018
4 201847004096-DRAWINGS [02-02-2018(online)].pdf 02 Feb 2018
5 201847004096-DECLARATION OF INVENTORSHIP (FORM 5) [02-02-2018(online)].pdf 02 Feb 2018
6 201847004096-COMPLETE SPECIFICATION [02-02-2018(online)].pdf 02 Feb 2018
7 abstract 201847004096.jpg 06 Feb 2018
8 201847004096-FORM 3 [04-08-2018(online)].pdf 04 Aug 2018
9 201847004096-Proof of Right (MANDATORY) [13-02-2019(online)].pdf 13 Feb 2019
10 Correspondence by Agent_Form1_18-02-2019.pdf 18 Feb 2019
11 201847004096-PA [20-02-2019(online)].pdf 20 Feb 2019
12 201847004096-ASSIGNMENT DOCUMENTS [20-02-2019(online)].pdf 20 Feb 2019
13 201847004096-8(i)-Substitution-Change Of Applicant - Form 6 [20-02-2019(online)].pdf 20 Feb 2019
14 201847004096-FORM 3 [03-07-2019(online)].pdf 03 Jul 2019
15 201847004096-FORM 18 [03-07-2019(online)].pdf 03 Jul 2019
16 201847004096-FORM 3 [26-08-2019(online)].pdf 26 Aug 2019
17 201847004096-FER.pdf 24 Feb 2020
18 201847004096-FORM 3 [13-03-2020(online)].pdf 13 Mar 2020
19 201847004096-PETITION UNDER RULE 137 [23-03-2020(online)].pdf 23 Mar 2020
20 201847004096-FORM 3 [24-03-2020(online)].pdf 24 Mar 2020
21 201847004096-FORM 4(ii) [30-07-2020(online)].pdf 30 Jul 2020
22 201847004096-FORM 3 [24-11-2020(online)].pdf 24 Nov 2020
23 201847004096-FER_SER_REPLY [24-11-2020(online)].pdf 24 Nov 2020
24 201847004096-DRAWING [24-11-2020(online)].pdf 24 Nov 2020
25 201847004096-CORRESPONDENCE [24-11-2020(online)].pdf 24 Nov 2020
26 201847004096-CLAIMS [24-11-2020(online)].pdf 24 Nov 2020
27 201847004096-ABSTRACT [24-11-2020(online)].pdf 24 Nov 2020
28 201847004096-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [13-05-2021(online)].pdf 13 May 2021
29 201847004096-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [18-06-2021(online)].pdf 18 Jun 2021
30 201847004096-US(14)-HearingNotice-(HearingDate-19-05-2021).pdf 17 Oct 2021
31 201847004096-US(14)-ExtendedHearingNotice-(HearingDate-27-10-2021).pdf 17 Oct 2021
32 201847004096-US(14)-ExtendedHearingNotice-(HearingDate-23-06-2021).pdf 17 Oct 2021
33 201847004096-Correspondence to notify the Controller [22-10-2021(online)].pdf 22 Oct 2021
34 201847004096-Written submissions and relevant documents [08-11-2021(online)].pdf 08 Nov 2021
35 201847004096-Annexure [08-11-2021(online)].pdf 08 Nov 2021
36 201847004096-PatentCertificate07-11-2023.pdf 07 Nov 2023
37 201847004096-IntimationOfGrant07-11-2023.pdf 07 Nov 2023
38 201847004096-FORM FOR SMALL ENTITY [16-07-2025(online)].pdf 16 Jul 2025
39 201847004096-EVIDENCE FOR REGISTRATION UNDER SSI [16-07-2025(online)].pdf 16 Jul 2025
Search strategy
12020-02-2015-45-15_20-02-2020.pdf

ERegister / renewals

Under Extension Period
3rd Renewed 07 Feb 2024 Period 28 Jul 2018 – 28 Jul 2019 · CBR 7920 · Certificate 23143 ₹4,000
4th Renewed 07 Feb 2024 Period 28 Jul 2019 – 28 Jul 2020 · CBR 7920 · Certificate 23144 ₹4,000
5th Renewed 07 Feb 2024 Period 28 Jul 2020 – 28 Jul 2021 · CBR 7920 · Certificate 23145 ₹4,000
6th Renewed 07 Feb 2024 Period 28 Jul 2021 – 28 Jul 2022 · CBR 7920 · Certificate 23146 ₹4,000
7th Renewed 07 Feb 2024 Period 28 Jul 2022 – 28 Jul 2023 · CBR 7920 · Certificate 23147 ₹12,000
8th Renewed 07 Feb 2024 Period 28 Jul 2023 – 28 Jul 2024 · CBR 7920 · Certificate 23148 ₹12,000
9th Renewed 07 Feb 2024 Period 28 Jul 2024 – 28 Jul 2025 · CBR 7920 · Certificate 23149 ₹12,000